Abstract

Short Review

Navigating Neurodegenerative Disorders: A Comprehensive Review of Current and Emerging Therapies for Neurodegenerative Disorders

Shashikant Kharat*, Sanjana Mali*, Gayatri Korade and Rakhi Gaykar

Published: 04 April, 2024 | Volume 8 - Issue 1 | Pages: 033-046

Neurodegenerative disorders (NDDs) pose a significant global health challenge, impacting millions with a gradual decline in neurons and cognitive abilities. Presently, available NDD therapies focus on symptom management rather than altering the disease trajectory. This underscores the critical necessity for groundbreaking treatments capable of addressing the root causes of neurodegeneration, offering both neuroprotection and neuro-restoration. This in-depth review delves into the forefront of emerging NDD therapies, encompassing gene therapy, stem cell therapy, immunotherapy, and neurotrophic factors. It sheds light on their potential advantages, hurdles, and recent advancements gleaned from both preclinical and clinical studies. Additionally, the document outlines existing NDD treatments, spanning pharmacological and non-pharmacological interventions, along with their inherent limitations. The overarching conclusion emphasizes the immense potential of emerging therapies in NDD treatment, yet underscores the imperative for continued research and optimization to ensure their safety, efficacy, and specificity.

Read Full Article HTML DOI: 10.29328/journal.jnnd.1001095 Cite this Article Read Full Article PDF

Keywords:

Neurodegenerative disorders; Therapeutic interventions; Gene therapy; Stem cell therapy; Emerging treatments’ RNAi; Neurotropic Factors

References

  1. Wilson DM 3rd, Cookson MR, Van Den Bosch L, Zetterberg H, Holtzman DM, Dewachter I. Hallmarks of neurodegenerative diseases. Cell. 2023 Feb 16;186(4):693-714. doi: 10.1016/j.cell.2022.12.032. PMID: 36803602.
  2. Merelli A, Czornyj L, Lazarowski A. Erythropoietin: a neuroprotective agent in cerebral hypoxia, neurodegeneration, and epilepsy. Curr Pharm Des. 2013;19(38):6791-801. doi: 10.2174/1381612811319380011. PMID: 23530506.
  3. Melo A, Monteiro L, Lima RM, Oliveira DM, Cerqueira MD, El-Bachá RS. Oxidative stress in neurodegenerative diseases: mechanisms and therapeutic perspectives. Oxid Med Cell Longev. 2011;2011:467180. doi: 10.1155/2011/467180. Epub 2011 Nov 24. PMID: 22191013; PMCID: PMC3236428.
  4. Lamptey RNL, Chaulagain B, Trivedi R, Gothwal A, Layek B, Singh J. A Review of the Common Neurodegenerative Disorders: Current Therapeutic Approaches and the Potential Role of Nanotherapeutics. Int J Mol Sci. 2022 Feb 6;23(3):1851. doi: 10.3390/ijms23031851. PMID: 35163773; PMCID: PMC8837071.
  5. Ding C, Wu Y, Chen X, Chen Y, Wu Z, Lin Z, Kang D, Fang W, Chen F. Global, regional, and national burden and attributable risk factors of neurological disorders: The Global Burden of Disease study 1990-2019. Front Public Health. 2022 Nov 29;10:952161. doi: 10.3389/fpubh.2022.952161. PMID: 36523572; PMCID: PMC9745318.
  6. Poddar KM, Chakraborty A, Banerjee S. Neurodegeneration: Diagnosis, Prevention, and Therapy. Oxidoreductase 2021.https://www.researchgate.net/publication/349117125_Neurodegeneration_Diagnosis_Prevention_and_Therapy
  7. Shusharina N, Yukhnenko D, Botman S, Sapunov V, Savinov V, Kamyshov G. Modern Methods of Diagnostics and Treatment of Neurodegenerative Diseases and Depression. Diagnostics. 2023; 13(3). /pmc/articles/PMC9914271/
  8. Xiao N, Le QT. Neurotrophic Factors and Their Potential Applications in Tissue Regeneration. Arch Immunol Ther Exp (Warsz). 2016 Apr;64(2):89-99. doi: 10.1007/s00005-015-0376-4. Epub 2015 Nov 26. PMID: 26611762; PMCID: PMC4805470.
  9. Pramanik S, Sulistio YA, Heese K. Neurotrophin Signaling and Stem Cells-Implications for Neurodegenerative Diseases and Stem Cell Therapy. Mol Neurobiol. 2017 Nov;54(9):7401-7459. doi: 10.1007/s12035-016-0214-7. Epub 2016 Nov 5. PMID: 27815842.
  10. Amyotrophic Lateral Sclerosis (ALS). National Institute of Neurological Disorders and Stroke. 2024. https://www.ninds.nih.gov/health-information/disorders/amyotrophic-lateral-sclerosis-als
  11. Keon M, Musrie B, Dinger M, Brennan SE, Santos J, Saksena NK. Destination Amyotrophic Lateral Sclerosis. Front Neurol. 2021 Mar 29;12:596006. doi: 10.3389/fneur.2021.596006. PMID: 33854469; PMCID: PMC8039771.
  12. Amyotrophic lateral sclerosis (ALS). Symptoms and causes - Mayo Clinic. 2024. https://www.mayoclinic.org/diseases-conditions/amyotrophic-lateral-sclerosis/symptoms-causes/syc-20354022
  13. Roos RAC. Huntington’s disease: A clinical review. Orphanet J Rare Dis. 2010; 5(1):1-8. https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-5-40
  14. Huntington Disease Article 2024. https://www.statpearls.com/ArticleLibrary/viewarticle/23053
  15. Rojas NG, Cesarini ME, Peker G, Andres G, Prat D, Luis Etcheverry J. Review of Huntington’s Disease: From Basics to Advances in Diagnosis and Treatment. J Neurol Res. 2022; 12(3):93-113. https://www.neurores.org/index.php/neurores/article/view/721/701
  16. Deture MA, Dickson DW. The neuropathological diagnosis of Alzheimer’s disease. Molecular Neurodegeneration 2019; 14:1; 1-18. https://molecularneurodegeneration.biomedcentral.com/articles/10.1186/s13024-019-0333-5
  17. Abubakar MB, Sanusi KO, Ugusman A, Mohamed W, Kamal H, Ibrahim NH, Khoo CS, Kumar J. Alzheimer's Disease: An Update and Insights Into Pathophysiology. Front Aging Neurosci. 2022 Mar 30;14:742408. doi: 10.3389/fnagi.2022.742408. PMID: 35431894; PMCID: PMC9006951.
  18. Breijyeh Z, Karaman R. Comprehensive Review on Alzheimer's Disease: Causes and Treatment. Molecules. 2020 Dec 8;25(24):5789. doi: 10.3390/molecules25245789. PMID: 33302541; PMCID: PMC7764106.
  19. Birks JS, Harvey RJ. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev. 2018 Jun 18;6(6):CD001190. doi: 10.1002/14651858.CD001190.pub3. PMID: 29923184; PMCID: PMC6513124.
  20. Areosa SA, Sherriff F, McShane R. Memantine for dementia. Cochrane Database Syst Rev. 2005 Jul 20;(3):CD003154. doi: 10.1002/14651858.CD003154.pub4. Update in: Cochrane Database Syst Rev. 2006;(2):CD003154. PMID: 16034889.
  21. Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA. 2014 Apr 23-30;311(16):1670-83. doi: 10.1001/jama.2014.3654. PMID: 24756517.
  22. Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2002;(2):CD001447. doi: 10.1002/14651858.CD001447. Update in: Cochrane Database Syst Rev. 2007;(1):CD001447. PMID: 12076411.
  23. Ballard C, Hanney ML, Theodoulou M, Douglas S, McShane R, Kossakowski K, Gill R, Juszczak E, Yu LM, Jacoby R; DART-AD investigators. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol. 2009 Feb;8(2):151-7. doi: 10.1016/S1474-4422(08)70295-3. Epub 2009 Jan 8. PMID: 19138567.
  24. Slade SC, Underwood M, McGinley JL, Morris ME. Exercise and Progressive Supranuclear Palsy: the need for explicit exercise reporting. BMC Neurol. 2019 Nov 29;19(1):305. doi: 10.1186/s12883-019-1539-4. PMID: 31783740; PMCID: PMC6884751.
  25. Tomlinson CL, Herd CP, Clarke CE, Meek C, Patel S, Stowe R, Deane KH, Shah L, Sackley CM, Wheatley K, Ives N. Physiotherapy for Parkinson's disease: a comparison of techniques. Cochrane Database Syst Rev. 2014 Jun 17;2014(6):CD002815. doi: 10.1002/14651858.CD002815.pub2. PMID: 24936965; PMCID: PMC7120367.
  26. Bahar-Fuchs A, Clare L, Woods B. Cognitive training and cognitive rehabilitation for mild to moderate Alzheimer's disease and vascular dementia. Cochrane Database Syst Rev. 2013 Jun 5;2013(6):CD003260. doi: 10.1002/14651858.CD003260.pub2. PMID: 23740535; PMCID: PMC7144738.
  27. Olazarán J, Reisberg B, Clare L, Cruz I, Peña-Casanova J, Del Ser T, Woods B, Beck C, Auer S, Lai C, Spector A, Fazio S, Bond J, Kivipelto M, Brodaty H, Rojo JM, Collins H, Teri L, Mittelman M, Orrell M, Feldman HH, Muñiz R. Nonpharmacological therapies in Alzheimer's disease: a systematic review of efficacy. Dement Geriatr Cogn Disord. 2010;30(2):161-78. doi: 10.1159/000316119. Epub 2010 Sep 10. PMID: 20838046.
  28. Sakthiswary R, Raymond AA. Stem cell therapy in neurodegenerative diseases: From principles to practice. Neural Regen Res. 2012 Aug 15;7(23):1822-31. doi: 10.3969/j.issn.1673-5374.2012.23.009. PMID: 25624807; PMCID: PMC4302533.
  29. Sivandzade F, Cucullo L. Regenerative Stem Cell Therapy for Neurodegenerative Diseases: An Overview. Int J Mol Sci. 2021 Feb 22;22(4):2153. doi: 10.3390/ijms22042153. PMID: 33671500; PMCID: PMC7926761.
  30. Brainstorm Cell Therapeutics Inc. Treating neurodegenerative diseases with stem cell therapy. 2024. https://www.nature.com/articles/d43747-020-00415-7
  31. Varma SK, Hyder MK, Som S, Dhanabal S. Stem cell therapy: in treatment of neurodegenerative diseases. J Stem Cell Res Ther (Edmond). 2018; 4(1). https://medcraveonline.com/JSRT/JSRT-04-00105.php
  32. Dantuma E, Merchant S, Sugaya K. Stem cells for the treatment of neurodegenerative diseases. Stem Cell Res Ther. 2010; 1(5):1-7. https://stemcellres.biomedcentral.com/articles/10.1186/scrt37
  33. Issa SS, Shaimardanova AA, Valiullin VV, Rizvanov AA, Solovyeva VV. Mesenchymal Stem Cell-Based Therapy for Lysosomal Storage Diseases and Other Neurodegenerative Disorders. Front Pharmacol. 2022 Mar 2;13:859516. doi: 10.3389/fphar.2022.859516. PMID: 35308211; PMCID: PMC8924473.
  34. Marsh SE, Blurton-Jones M. Neural stem cell therapy for neurodegenerative disorders: The role of neurotrophic support. Neurochem Int. 2017 Jun;106:94-100. doi: 10.1016/j.neuint.2017.02.006. Epub 2017 Feb 20. PMID: 28219641; PMCID: PMC5446923.
  35. Ravisankar P, Dhanavardhan K, Prathyusha K, Rajan KV. Stem cell therapy role in neurodegenerative disorders. Archives of Mental Health. 2018; 19(1):3.
  36. Vissers C, Ming GL, Song H. Nanoparticle technology and stem cell therapy team up against neurodegenerative disorders. Adv Drug Deliv Rev. 2019 Aug;148:239-251. doi: 10.1016/j.addr.2019.02.007. Epub 2019 Feb 21. PMID: 30797953; PMCID: PMC6703981.
  37. Yan SS, Campos de Souza S, Xie ZD, Bao YX. Research progress in clinical trials of stem cell therapy for stroke and neurodegenerative diseases. Ibrain. 2023; 9(2):214-30. https://onlinelibrary.wiley.com/doi/full/10.1002/ibra.12095
  38. Fan Y, Goh ELK, Chan JKY. Neural Cells for Neurodegenerative Diseases in Clinical Trials. Stem Cells Transl Med. 2023 Aug 16;12(8):510-526. doi: 10.1093/stcltm/szad041. PMID: 37487111; PMCID: PMC10427968.
  39. Enzo Life Sciences. Stem Cell Therapy in Neurodegenerative Diseases. 2019. https://www.enzolifesciences.com/science-center/technotes/2019/june/stem-cell-therapy-in-neurodegenerative-diseases/
  40. Sugaya K, Vaidya M. Stem Cell Therapies for Neurodegenerative Diseases. Adv Exp Med Biol. 2018;1056:61-84. doi: 10.1007/978-3-319-74470-4_5. PMID: 29754175.
  41. Wei M, Yang Z, Li S, Le W. Nanotherapeutic and Stem Cell Therapeutic Strategies in Neurodegenerative Diseases: A Promising Therapeutic Approach. Int J Nanomedicine. 2023 Feb 3;18:611-626. doi: 10.2147/IJN.S395010. PMID: 36760756; PMCID: PMC9904216.
  42. Wang Q, Song LJ, Ding ZB, Chai Z, Yu JZ, Xiao BG, Ma CG. Advantages of Rho-associated kinases and their inhibitor fasudil for the treatment of neurodegenerative diseases. Neural Regen Res. 2022 Dec;17(12):2623-2631. doi: 10.4103/1673-5374.335827. PMID: 35662192; PMCID: PMC9165373.
  43. Pourjabbar B, Shams F, Moghadam M, Ahani-Nahayati M, Azari A, Sefat F, Keshel SH. Recent Emerging Trend in Stem Cell Therapy Risk Factors. Curr Stem Cell Res Ther. 2023;18(8):1076-1089. doi: 10.2174/1574888X18666221223104859. PMID: 36567298.
  44. Rahman MM, Islam MR, Islam MT, Harun-Or-rashid M, Islam M, Abdullah S. Stem Cell Transplantation Therapy and Neurological Disorders: Current Status and Future Perspectives. Biology (Basel). 2022; 11(1). /pmc/articles/PMC8772847/
  45. Sudhakar V, Richardson RM. Gene Therapy for Neurodegenerative Diseases. Neurotherapeutics. 2019 Jan;16(1):166-175. doi: 10.1007/s13311-018-00694-0. PMID: 30542906; PMCID: PMC6361055.
  46. Notarte KI, Catahay JA, Macasaet R, Liu J, Velasco JV, Peligro PJ, Vallo J, Goldrich N, Lahoti L, Zhou J, Henry BM. Infusion reactions to adeno-associated virus (AAV)-based gene therapy: Mechanisms, diagnostics, treatment and review of the literature. J Med Virol. 2023 Dec;95(12):e29305. doi: 10.1002/jmv.29305. PMID: 38116715.
  47. Zu H, Gao D. Non-viral Vectors in Gene Therapy: Recent Development, Challenges, and Prospects. AAPS J. 2021 Jun 2;23(4):78. doi: 10.1208/s12248-021-00608-7. PMID: 34076797; PMCID: PMC8171234.
  48. Vaughan EE, DeGiulio JV, Dean DA. Intracellular trafficking of plasmids for gene therapy: mechanisms of cytoplasmic movement and nuclear import. Curr Gene Ther. 2006 Dec;6(6):671-681. doi: 10.2174/156652306779010688. PMID: 17168698; PMCID: PMC4400175.
  49. Kanter J, Falcon C. Gene therapy for sickle cell disease: where we are now? Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):174-180. doi: 10.1182/hematology.2021000250. PMID: 34889358; PMCID: PMC8791177.
  50. Chulpanova DS, Shaimardanova AA, Ponomarev AS, Elsheikh S, Rizvanov AA, Solovyeva VV. Current Strategies for the Gene Therapy of Autosomal Recessive Congenital Ichthyosis and Other Types of Inherited Ichthyosis. Int J Mol Sci. 2022 Feb 24;23(5):2506. doi: 10.3390/ijms23052506. PMID: 35269649; PMCID: PMC8910354.
  51. Maule G, Arosio D, Cereseto A. Gene Therapy for Cystic Fibrosis: Progress and Challenges of Genome Editing. Int J Mol Sci. 2020 May 30;21(11):3903. doi: 10.3390/ijms21113903. PMID: 32486152; PMCID: PMC7313467.
  52. Mani S, Jindal D, Singh M. Gene Therapy, A Potential Therapeutic Tool for Neurological and Neuropsychiatric Disorders: Applications, Challenges and Future Perspective. Curr Gene Ther. 2023;23(1):20-40. doi: 10.2174/1566523222666220328142427. PMID: 35345999.
  53. Al-Saif AM. Gene therapy of hematological disorders: current challenges. Gene Ther. 2019 Aug;26(7-8):296-307. doi: 10.1038/s41434-019-0093-4. Epub 2019 Jul 12. PMID: 31300728.
  54. Kumar SR, Markusic DM, Biswas M, High KA, Herzog RW. Clinical development of gene therapy: results and lessons from recent successes. Mol Ther Methods Clin Dev. 2016 May 25;3:16034. doi: 10.1038/mtm.2016.34. PMID: 27257611; PMCID: PMC4879992.
  55. Matharu N, Ahituv N. Modulating gene regulation to treat genetic disorders. Nat Rev Drug Discov. 2020 Nov;19(11):757-775. doi: 10.1038/s41573-020-0083-7. Epub 2020 Oct 5. PMID: 33020616.
  56. Hibbitt O, Wade-Martins R. Physiologically-Regulated Expression Vectors for Gene Therapy. In: Targets in Gene Therapy. InTech. 2011.
  57. Picanço-Castro V, Pereira CG, Covas DT, Porto GS, Athanassiadou A, Figueiredo ML. Emerging patent landscape for non-viral vectors used for gene therapy. Nat Biotechnol. 2020 Feb;38(2):151-157. doi: 10.1038/s41587-019-0402-x. PMID: 32034383; PMCID: PMC7308177.
  58. Kariyawasam D, Alexander IE, Kurian M, Farrar MA. Great expectations: virus-mediated gene therapy in neurological disorders. J Neurol Neurosurg Psychiatry. 2020 Aug;91(8):849-860. doi: 10.1136/jnnp-2019-322327. Epub 2020 Jun 5. PMID: 32503884.
  59. Hitti FL, Yang AI, Gonzalez-Alegre P, Baltuch GH. Human gene therapy approaches for the treatment of Parkinson's disease: An overview of current and completed clinical trials. Parkinsonism Relat Disord. 2019 Sep;66:16-24. doi: 10.1016/j.parkreldis.2019.07.018. Epub 2019 Jul 13. PMID: 31324556.
  60. Fuller-Carter PI, Basiri H, Harvey AR, Carvalho LS. Focused Update on AAV-Based Gene Therapy Clinical Trials for Inherited Retinal Degeneration. BioDrugs. 2020 Dec;34(6):763-781. doi: 10.1007/s40259-020-00453-8. PMID: 33136237.
  61. Martier R, Konstantinova P. Gene Therapy for Neurodegenerative Diseases: Slowing Down the Ticking Clock. Front Neurosci. 2020 Sep 18;14:580179. doi: 10.3389/fnins.2020.580179. PMID: 33071748; PMCID: PMC7530328.
  62. Morgan D. Immunotherapy for Neurodegenerative Disorders. Oxford University Press. 2016; 1.
  63. Kwon S, Iba M, Kim C, Masliah E. Immunotherapies for Aging-Related Neurodegenerative Diseases-Emerging Perspectives and New Targets. Neurotherapeutics. 2020 Jul;17(3):935-954. doi: 10.1007/s13311-020-00853-2. PMID: 32347461; PMCID: PMC7222955.
  64. Nicoll J. https://meetings.bna.org.uk/bna2023/prog/programme-day/immunotherapy-in-neurodegenerative-diseases/. 2023. IMMUNOTHERAPY IN NEURODEGENERATIVE DISEASES.
  65. Brody DL, Holtzman DM. Active and passive immunotherapy for neurodegenerative disorders. Annu Rev Neurosci. 2008;31:175-93. doi: 10.1146/annurev.neuro.31.060407.125529. PMID: 18352830; PMCID: PMC2561172.
  66. Mortada I, Farah R, Nabha S, Ojcius DM, Fares Y, Almawi WY, Sadier NS. Immunotherapies for Neurodegenerative Diseases. Front Neurol. 2021 Jun 7;12:654739. doi: 10.3389/fneur.2021.654739. PMID: 34163421; PMCID: PMC8215715.
  67. Chatterjee D, Kordower JH. Immunotherapy in Parkinson's disease: Current status and future directions. Neurobiol Dis. 2019 Dec;132:104587. doi: 10.1016/j.nbd.2019.104587. Epub 2019 Aug 25. PMID: 31454546.
  68. White AR, Hawke SH. Immunotherapy as a therapeutic treatment for neurodegenerative disorders. J Neurochem. 2003 Nov;87(4):801-8. doi: 10.1046/j.1471-4159.2003.02064.x. PMID: 14622111.
  69. Weissmiller AM, Wu C. Current advances in using neurotrophic factors to treat neurodegenerative disorders. Transl Neurodegener. 2012; 1(1):1-9. https://translationalneurodegeneration.biomedcentral.com/articles/10.1186/2047-9158-1-14
  70. Blesch A. Neurotrophic factors in neurodegeneration. Brain Pathol. 2006 Oct;16(4):295-303. doi: 10.1111/j.1750-3639.2006.00036.x. PMID: 17107599; PMCID: PMC8095767.
  71. Bhardwaj R, Deshmukh R. Neurotrophic factors and Parkinson’s disease. Clin Investig (Lond). 2017; 8(1):53-62. https://www.openaccessjournals.com/articles/neurotrophic-factors-and-parkinsons-disease-12412.html
  72. Ouaamari ElY, Bos VDJ, Willekens B, Cools N, Wens I. Neurotrophic Factors as Regenerative Therapy for Neurodegenerative Diseases: Current Status, Challenges and Future Perspectives. Int J Mol Sci. 2023; 24(4). /pmc/articles/PMC9968045/
  73. Garcia de Yebenes J, Yebenes J, Mena MA. Neurotrophic factors in neurodegenerative disorders: model of Parkinson's disease. Neurotox Res. 2000;2(2-3):115-37. doi: 10.1007/BF03033789. PMID: 16787836.
  74. Boudreau RL, Davidson BL. RNAi therapy for neurodegenerative diseases. Curr Top Dev Biol. 2006;75:73-92. doi: 10.1016/S0070-2153(06)75003-7. PMID: 16984810.
  75. Gonzalez-Alegre P. Therapeutic RNA interference for neurodegenerative diseases: From promise to progress. Pharmacol Ther. 2007 Apr;114(1):34-55. doi: 10.1016/j.pharmthera.2007.01.003. Epub 2007 Jan 25. PMID: 17316816.
  76. Sah DW. Therapeutic potential of RNA interference for neurological disorders. Life Sci. 2006 Oct 4;79(19):1773-80. doi: 10.1016/j.lfs.2006.06.011. Epub 2006 Jun 15. PMID: 16815477.
  77. Orlacchio A, Bernardi G, Orlacchio A, Martino S. RNA interference as a tool for Alzheimer's disease therapy. Mini Rev Med Chem. 2007 Nov;7(11):1166-76. doi: 10.2174/138955707782331678. PMID: 18045220.

Figures:

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?